文献速递腹部CTMR

LI-RADS 用于诊断非肝硬化慢性丙型肝炎患者肝细胞癌

LI-RADS for Diagnosing Hepatocellular Carcinoma in Patients with Noncirrhotic Chronic Hepatitis C.
PubMed 文献 · Radiology · 2025-01-01

本回顾性研究评估 LI-RADS 5 类(LR-5,提示明确肝细胞癌)在非肝硬化慢性丙型肝炎患者中经 CT 和 MRI 诊断肝细胞癌的表现,并与肝硬化慢性丙型肝炎患者比较。测试集 458 例中非肝硬化组 AUC 0.90、敏感度 82.4%、特异度 97.6%;验证集 103 例 155 个病灶 AUC 0.91、敏感度 82.9%、特异度 100%。非肝硬化组 AUC 高于肝硬化组(0.90 vs 0.79,P=0.002)。

要点

  • 非肝硬化慢性丙型肝炎患者中,LR-5 诊断肝细胞癌的 AUC 为 0.90,敏感度 82.4%,特异度 97.6%。
  • 非肝硬化组 LR-5 诊断肝细胞癌的 AUC 高于肝硬化组(0.90 vs 0.79,P=0.002)。
  • 验证集中 LR-5 诊断肝细胞癌的 AUC 为 0.91,敏感度 82.9%,特异度 100%。

核心结论

  • 在非肝硬化慢性丙型肝炎患者中,LR-5 诊断肝细胞癌的表现与肝硬化患者相当,且在不同临床场景中一致。

研究设计与样本

  • 回顾性研究,测试集纳入 2002 年 8 月至 2022 年 2 月在两家大学医院行动态 CT 或 MRI 检查、病灶≥1 cm 且经病理证实的慢性丙型肝炎患者 458 例(平均年龄 64 岁±9,男 350 例,非肝硬化 219 例、肝硬化 239 例)。
  • 以病理为参考标准计算 LR-5 诊断肝细胞癌的敏感度、特异度和 AUC;CT 与 MRI 的 LI-RADS 分类不一致时以 MRI 分类为最终分类。
  • 验证集来自另外两家医院、基于临床复合参考标准的慢性丙型肝炎患者 103 例(平均年龄 68 岁±12,男 146 例),共 155 个病灶。

诊断标准与关键数值

  • 非肝硬化组 LR-5 诊断肝细胞癌的 AUC 0.90(95%CI 0.86, 0.93)、准确率 85.1%(95%CI 80.6, 89.7)、敏感度 82.4%(95%CI 77.0, 87.8)、特异度 97.6%(95%CI 93.0, 100.0)、阳性预测值 99.4%(95%CI 98.2, 100.0)、阴性预测值 54.7%(95%CI 43.4, 65.9)。
  • 非肝硬化组与肝硬化组 LR-5 诊断肝细胞癌的 AUC 分别为 0.90(95%CI 0.86, 0.93)和 0.79(95%CI 0.74, 0.84),非肝硬化组更高(P=0.002)。
  • 验证集 LR-5 诊断肝细胞癌的 AUC 0.91(95%CI 0.84, 0.97)、准确率 96.1%(95%CI 93.1, 99.2)、敏感度 82.9%(95%CI 70.4, 95.3)、特异度 100%、阳性预测值 100%、阴性预测值 95.2%(95%CI 91.5, 99.0)。

临床应用与阅片要点

  • 在非肝硬化慢性丙型肝炎患者中,LR-5 对肝细胞癌具有很高的特异度和阳性预测值,诊断表现与肝硬化患者相当。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background The Liver Imaging Reporting and Data System (LI-RADS) criteria have not been validated for patients with noncirrhotic chronic hepatitis C (CHC), who are at a greater risk for hepatocellular carcinoma (HCC) than the general population. Purpose To evaluate the diagnostic performance of LI-RADS category 5 (LR-5, indicating definite HCC) observations for HCC using CT and MRI in patients with noncirrhotic CHC and to compare these findings with those in patients with cirrhotic CHC. Materials and Methods This retrospective study included patients without cirrhosis with CHC with focal hepatic nodules of 1 cm or greater on dynamic CT or MRI scans who underwent pathologic confirmation at two university hospitals from August 2002 to February 2022. This group served as the test dataset. The primary outcome was the diagnostic performance of LR-5 for HCC using CT and MRI. When LI-RADS categorization differed between CT and MRI, the MRI-based classification was used as the definitive category. Results were validated using a dataset of patients with CHC from two additional hospitals based on the clinical composite reference standard. Sensitivity, specificity, and area under the receiver operating characteristic curve (AUC) were calculated. Results The test dataset comprised 458 patients (mean age, 64 years ± 9 [SD]; 350 male; 219 without cirrhosis, 239 with cirrhosis). For noncirrhotic livers, the LR-5 criteria achieved an AUC, accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of 0.90 (95% CI: 0.86, 0.93), 85.1% (95% CI: 80.6, 89.7), 82.4% (95% CI: 77.0, 87.8), 97.6% (95% CI: 93.0, 100.0), 99.4% (95% CI: 98.2, 100.0), and 54.7% (95% CI: 43.4, 65.9), respectively. The AUC for LR-5 observations in diagnosing HCC was higher in the noncirrhotic liver group compared with the cirrhotic liver group (AUC, 0.90 [95% CI: 0.86, 0.93] vs 0.79 [95% CI: 0.74, 0.84]; P = .002). The diagnostic performance of the LR-5 criteria for diagnosing HCC was also excellent in patients with noncirrhotic CHC in the validation dataset, which included 155 lesions from 103 patients (mean age, 68 years ± 12; 146 male). The AUC, accuracy, sensitivity, specificity, PPV, and NPV in the validation dataset were 0.91 (95% CI: 0.84, 0.97), 96.1% (95% CI: 93.1, 99.2), 82.9% (95% CI: 70.4, 95.3), 100%, 100%, and 95.2% (95% CI: 91.5, 99.0), respectively. Conclusion The diagnostic performance of LR-5 for HCC in patients with noncirrhotic CHC was comparable to that in patients with cirrhosis across various clinical settings. © RSNA, 2025 Supplemental material is available for this article. See also the editorial by Schöllnast in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. An J, Park R, Kim E, et al. LI-RADS for Diagnosing Hepatocellular Carcinoma in Patients with Noncirrhotic Chronic Hepatitis C. Radiology. 2025. PMID: 40131114. doi:10.1148/radiol.241856

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。